Nonalcoholic steatohepatitis

Current Treatment Options in Gastroenterology

Volumn 7, Issue 6, 2004, Pages 423-430

  Mulhall, Brian P ^a   Younossi, Zobair M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMINO ACID; AMINOTRANSFERASE; ANTIBIOTIC AGENT; ASCORBIC ACID; BETAINE; BILE ACID; BILIRUBIN; CLOFIBRATE; CREATINE KINASE; FIBRIC ACID DERIVATIVE; FREE RADICAL; GEMFIBROZIL; INSULIN; LACTIC ACID; LIGAND; LIPID; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PROBUCOL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN;

ABDOMINAL PAIN; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTHRITIS; ARTICLE; BACKACHE; BILIOPANCREATIC BYPASS; BILIRUBIN BLOOD LEVEL; BODY WEIGHT DISORDER; BONE MARROW HYPOPLASIA; CELL DEGENERATION; CHILL; CHOLECYSTITIS; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSPEPSIA; DYSPNEA; ECZEMA; EDEMA; EPIDEMIOLOGICAL DATA; EXFOLIATIVE DERMATITIS; FAINTNESS; FATIGUE; FEVER; FLANK PAIN; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; GASTROPLASTY; GONAD DYSFUNCTION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEARTBURN; HEPATITIS; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; HYPEROXALURIA; HYPOGLYCEMIA; INCIDENCE; INCONTINENCE; INTESTINE BYPASS; LACTIC ACIDOSIS; LEUKOPENIA; LIFESTYLE; LIPID PEROXIDATION; LIPID STORAGE; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER PARENCHYMA; LUNG EDEMA; MALLORY BODY; MEGALOBLASTIC ANEMIA; MENSTRUAL IRREGULARITY; METABOLIC SYNDROME X; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYASTHENIA; MYOPATHY; NAUSEA; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PANCREATITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PREVALENCE; PRURITUS; PUBLIC HEALTH; QT PROLONGATION; RAYNAUD PHENOMENON; RETINA EDEMA; RHABDOMYOLYSIS; RISK FACTOR; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STOMACH BYPASS; STOMATITIS; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 9744268257     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0001-9     Document Type: Article

References (62)

1. Younossi ZM: Nonalcoholic fatty liver disease. Curr Gastroenterol Rep 1999, 1:57-62.
2. Falck-Ytter Y, Younossi ZM, Marchesini G, et al.: Clinical features and natural history of nonalcoholic steatosis syndromes. Sem Liver Dis 2001, 21:17-26.
3. Bacon BR, Farahvash MJ, Janney CG, et al.: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
4. Matteoni CA, Younossi ZM, Gramlich T, et al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
5. Teli MR, James OF, Burt AD, et al.: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
6. ixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
7. Angulo P, Keach JC, Batts KP, et al.: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
8. Gramlich T, Kleiner D, McCullough A, et al.: Pathologic Features Associated with Fibrosis in Non-Alcoholic Fatty Liver Disease. Hum Pathol 2004, 35:196-199.
9. Ratziu V, Giral P, Charlotte F, et al.: Liver fibrosis in overweight patients. Gastroenterology 2000, 118: 117-23.
10. Younossi ZM, Gramlich T, Bacon BR, et al.: Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999, 30:847-850.
11. Ong JP, Younossi ZM, Speer C, et al.: Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001, 21:266-271.
12. Clark JM., Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649-1657.
13. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
14. Weltman MD, Farrell GC, Hall P, et al.: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
15. Younossi ZM, Gramlich T, Matteoni CA, et al.: Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004, 2:262-265.
16. Caldwell SH, Oelsner DH, Iezzoni JC, et al.: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
17. Ong J, Younossi ZM, Reddy V, et al.: Cryptogenic cirrhosis and posttransplant nonalcoholic fatty liver disease. Liver Transpl 2001, 7:797-801.
18. Saadeh S, Younossi ZM, Remer EM, et al.: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
19. Siegelman ES, Rosen MA: Imaging of hepatic steatosis. Semin Liver Dis 2001, 21:71-80.
20. Younossi AM, Gramlich T, Liu YC: Nonalcoholic fatty liver disease: assessments of variability in pathologic interpretations. Mod Pathol 1998, 11:560-565.
21. Brunt EM, Janney CG, Di Bisceglie AM, et al.: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94: 467-2474.
22. Diehl AM, Goodman Z, Ishak KG: Alcohol-like liver disease in non-alcoholics. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterology 1988, 95: 056-1062.
23. Becker U, Gronbaek M, Johansen D, et al.: Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002, 35:868-875.
24. Day CP, James OFW: Steatohepatitis: a tale of two "hits"? Gastroenterology 1998, 114:842-845.
25. Paradis V, Perlemuter G, Bonvoust F, et al.: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738-744.
26. Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001, 21:27-41.5.
27. Leclercq IA, Farrell GC, Field J, et al.: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000, 105:1067-1075.
28. Pessayre D, Mansouri A, Haouzi D, et al.: Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999,15:367-373.
29. Rao MS, Reddy JK: Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001, 21:43-55.
30. Whelan G, Wood B: The metabolic consequences of jejunoileal bypass for obesity. Aust N Z J Surg 1980, 50: 20-524.
31. Giannini E, Barreca T, Testa R: Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? Am J Gastroenterol 2001, 96:2519-2520.
32. Kaplan LM: Leptin, obesity, and liver disease. Gastroenterology 1998,115:997-1001.
33. Uygun A, Kadayifci A, Yesilova Z, et al.: Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000, 95:3584-9.
34. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408-1413.
35. Anderson T, Gluud C, Franzmann MB, et al.: Hepatic effects of dietary weight loss in morbidly obese patients. Gastroenterology 1991, 12:224-229.
36. Ueno T, Sugawara H, Sujaku K, et al.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103-107.
37. Wang RT, Koretz RL, Yee HF, Jr: Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003, 115:554-559.
38. Rozental P, Biava C, Spencer H, et al.: Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967, 12:198-208.
39. Drenick EJ, Fisler J, Johnson D: Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982, 82: 35-548.
40. Harrison SA, Torgerson S, Hayashi P, et al.: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98:2485-2490.
41. Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999, 31:384.
42. Miglio F, Rovati LC, Santoro A, et al.: Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000, 50:722-727.
43. Lindor KD, Kowdley KV, Heathcote EJ, et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39: 70-778.
44. Merat S, Malekzadeh R, Sohrabi MR, et al.: Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003, 38:414-418.
45. Katoh S, Hata S, Matsushima M, et al.: Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial. Metabolism 2001, 50:414-417.
46. Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986, 220:83-88.
47. Campbell JM, Hunt TK, Karam JH, et al.: Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 1977, 137:602-610.
48. Rogus J, Blumenthal SA: Variations in dietary intake after bypass surgery for obesity. Possible relation to development of fatty liver after jejunoileal bypass. J Am Diet Assoc 1981, 79: 37-440.
49. Kral JG, Thung SN, Biron S, et al.: Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004, 135:48-58.
50. DixonJB,PrithiSB,HughesNR,O'BrienPE: Non-alcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.Hepatology 2004, 39:1647-1654.
51. Caldwell SH, Hespenheide EE, Redick JA, et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:519-25.
52. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al.: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38: 008-1017.
53. Itoh S, Kanazuka A, Akimoto T: Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003, 48: 182-2186.
54. Promrat K, Lutchman G, Uwaifo GI, et al.: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
55. Shadid S, Jensen MD: Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 2003, 1:384-387.
56. Marchesini G, Brizi M, Bianchi G, et al.: Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358: 93-894.
57. Laurin J, Lindor KD, Crippin JS, et al.: Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study. Hepatology 1996, 23: 464-1467.
58. Sabuncu T, Nazligul Y, Karaoglanoglu M, et al.: The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003, 12: 89-192.
59. Harrison SA, Ramrakhiani S, Brunt EM, et al.: Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003, 98:926-930.
60. Abdelmalek MF, Angulo P, Jorgensen RA, et al.: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96:2711-2717.
61. Lavine JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000, 136:734-738.
62. Gulbahar O, Karasu ZA, Ersoz G, et al.: Treatment of nonalcoholic steatohepatitis with N-acetylcysteine. [abstract]. Gastroenterology 2000, 118:A1444.